157 related articles for article (PubMed ID: 8325902)
1. The role of platinum dose intensity in the management of ovarian cancer.
Markman M
J Cancer Res Clin Oncol; 1993; 119(9):511-2. PubMed ID: 8325902
[No Abstract] [Full Text] [Related]
2. Optimal dosing with carboplatin.
Ozols RF
Semin Oncol; 1989 Apr; 16(2 Suppl 5):14-8. PubMed ID: 2655094
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin substitution for cisplatin in the treatment of ovarian carcinoma--a word of caution.
McGuire WP; Abeloff MD
J Natl Cancer Inst; 1989 Oct; 81(19):1438-9. PubMed ID: 2674458
[No Abstract] [Full Text] [Related]
4. Comparative intraperitoneal pharmacokinetics of three platinum analogues.
Lind MJ; Murphy DJ; Sharma H; Tinker N; Smith A; McAuliffe CA; Crowther D
Cancer Chemother Pharmacol; 1991; 28(4):315-7. PubMed ID: 1879050
[TBL] [Abstract][Full Text] [Related]
5. High dose cisplatin and high dose carboplatin in refractory ovarian cancer.
Ozols RF; Behrens BC; Ostchega Y; Young RC
Cancer Treat Rev; 1985 Sep; 12 Suppl A():59-65. PubMed ID: 3910223
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin in the first-line chemotherapy of ovarian cancer.
Alberts DS; Canetta R; Mason-Liddil N
Semin Oncol; 1990 Feb; 17(1 Suppl 2):54-60. PubMed ID: 2406922
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin.
Mangioni C; Bolis G; Pecorelli S; Bragman K; Epis A; Favalli G; Gambino A; Landoni F; Presti M; Torri W
J Natl Cancer Inst; 1989 Oct; 81(19):1464-71. PubMed ID: 2674459
[TBL] [Abstract][Full Text] [Related]
8. The role of intraperitoneal chemotherapy in ovarian cancer.
Markman M
Clin Adv Hematol Oncol; 2006 Nov; 4(11):809-10. PubMed ID: 17143249
[No Abstract] [Full Text] [Related]
9. Carboplatin equals cisplatin: but how do I prescribe it?
Gore M
J Clin Oncol; 2003 Sep; 21(17):3183-5. PubMed ID: 12860965
[No Abstract] [Full Text] [Related]
10. High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease.
Lund B; Hansen M; Hansen OP; Hansen HH
J Clin Oncol; 1989 Oct; 7(10):1469-73. PubMed ID: 2674334
[TBL] [Abstract][Full Text] [Related]
11. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.
Covens A; Carey M; Bryson P; Verma S; Fung Kee Fung M; Johnston M
Gynecol Oncol; 2002 Apr; 85(1):71-80. PubMed ID: 11925123
[TBL] [Abstract][Full Text] [Related]
12. Carboplatin in the treatment of ovarian cancer.
Alberts DS; Mason-Liddil N
Semin Oncol; 1989 Apr; 16(2 Suppl 5):19-26. PubMed ID: 2655095
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
[No Abstract] [Full Text] [Related]
14. Establishment of human ovarian tumour lines in nude mice and their responses to platinum analogues.
Sawada M; Ozaki M; Mori Y; Taniguchi H; Tateishi R; Wada A
Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1219-23. PubMed ID: 3308485
[No Abstract] [Full Text] [Related]
15. Dose intensity in advanced ovarian cancer: have we answered the question?
Fennelly D
Clin Cancer Res; 1995 Jun; 1(6):575-82. PubMed ID: 9816018
[No Abstract] [Full Text] [Related]
16. Dose intensity of carboplatin in combination with cyclophosphamide or ifosfamide.
Green JA; Smith K
Cancer Chemother Pharmacol; 1990; 26 Suppl():S22-5. PubMed ID: 2189593
[TBL] [Abstract][Full Text] [Related]
17. In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines.
Perez RP; Perez KM; Handel LM; Hamilton TC
Cancer Chemother Pharmacol; 1992; 29(6):430-4. PubMed ID: 1568285
[TBL] [Abstract][Full Text] [Related]
18. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
Levin L; Simon R; Hryniuk W
J Natl Cancer Inst; 1993 Nov; 85(21):1732-42. PubMed ID: 8411257
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin.
Med Lett Drugs Ther; 1989 Sep; 31(800):83-4. PubMed ID: 2671623
[No Abstract] [Full Text] [Related]
20. High-dose carboplatin in refractory ovarian cancer patients.
Ozols RF; Ostchega Y; Curt G; Young RC
J Clin Oncol; 1987 Feb; 5(2):197-201. PubMed ID: 3543243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
